This new article publication from Acta Pharmaceutica Sinica B, discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...

Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...

Scientists at Walter and Elizabeth Hall Institute (WEHI) have made what they describe as a huge leap forward in the fight against Parkinson’s disease, solving a decades-long mystery by determining the ...

Researchers provide essential insights on the molecular activation of the MAP kinase p38?, the final switch triggering the inflammatory response. Inflammation is a cellular coping mechanism when ...

In the wee hours of an October morning, David Baker, a protein biologist at the University of Washington (UW), received the most-awaited phone call in a scientist’s career. Halfway around the world, ...

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University led have uncovered how targeted lung cancer drugs alter the shape and behavior of a ...